Centessa: Hemophilia B Data Readout In 2024 Is Major Turning Point [Seeking Alpha]
Centessa Pharmaceuticals plc - American Depositary Shares (CNTA)
Company Research
Source: Seeking Alpha
PRESent-3 is another registrational study using SerpinPC for the treatment of patients with Hemophilia B, however it is for the targeting of such patients with inhibitors. ORX750 is an oral selective orexin receptor agonist being developed for the treatment of patients with Narcolepsy Type 1; Proof of concept data to be released in second half 2024. LB101 is another product in the pipeline with great potential targeting solid tumors, because it utilizes proven targeted proteins such as PD-L1 and CD47; The PD-L1 blockade occurs first as a block mechanism then with hinges dissolving moves the CD47 into place to perform mechanism of action. Centessa Pharmaceuticals plc NASDAQ: CNTA ) is gearing up to report interim results from one of its two registrational studies, known as PRESent-2 in 2024. This will be a major catalyst for investors to look forward to Recommended For You Recommended For You
Show less
Read more
Impact Snapshot
Event Time:
CNTA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CNTA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CNTA alerts
High impacting Centessa Pharmaceuticals plc - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
CNTA
News
- Iktos announces the appointment of Roman Fleck as Chairman of the Board [Yahoo! Finance]Yahoo! Finance
- Iktos announces the appointment of Roman Fleck as Chairman of the Board GlobeNewswire
- Centessa Pharmaceuticals Announces Pricing of $100 Million Public Offering of American Depositary Shares [Yahoo! Finance]Yahoo! Finance
- Centessa Pharmaceuticals Announces Pricing of $100 Million Public Offering of American Depositary SharesGlobeNewswire
- Centessa Pharmaceuticals Announces $100 Million Proposed Public Offering of American Depositary Shares [Yahoo! Finance]Yahoo! Finance
CNTA
Earnings
- 11/13/23 - Beat
CNTA
Sec Filings
- 4/26/24 - Form PRE
- 4/25/24 - Form 424B5
- 4/24/24 - Form 8-K
- CNTA's page on the SEC website